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AbOBJECTIVES The authors sought to evaluate 1-year clinical outcomes with the Lotus valve (Boston Scientiﬁc, Marl-
borough, Massachusetts) in a large international, multicenter prospective registry including patients eligible for trans-
catheter aortic valve replacement (TAVR) based on heart team consensus.
BACKGROUND TAVR is a safe and effective treatment for severe aortic valve stenosis; however, limited data are
available on TAVR with the repositionable and fully retrievable Lotus valve in unrestricted contemporary clinical practice.
METHODS The RESPOND (Repositionable Lotus Valve System—Post-Market Evaluation of Real World Clinical
Outcomes) study enrolled 1,014 patients; 996 patients were implanted with the Lotus valve (mean age 80.8 years,
50.8% female, mean STS score 6.0  6.9%). The primary endpoint was all-cause mortality in the intent-to-treat pop-
ulation at 30 days and 1 year. An Extension cohort of 50 patients was treated with the Lotus valve with Depth Guard
including a modiﬁed delivery system. Mortality and stroke were independently adjudicated. An independent core labo-
ratory assessed echocardiographic data.
RESULTS One-year clinical follow-up was available for 99.9% of Lotus valve-treated patients. At 1 year, the all-cause
mortality rate was 11.7% and 4.1% of patients had experienced a disabling stroke. The permanent pacemaker implan-
tation rate was 32% (37% among pacemaker-naive patients). Echocardiographic data at 1 year were available for core
laboratory assessment in 62.6% of patients. Paravalvular leak was absent or trace in 94.5%, mild in 5.1%, and moderate
in 0.4% of patients. Data from the Extension cohort conﬁrmed good clinical outcomes at 30 days with an 18% permanent
pacemaker rate (20% among pacemaker-naive patients).
CONCLUSIONS One-year outcomes from the RESPOND study conﬁrm the safety and efﬁcacy of the Lotus valve
when used in routine clinical practice. (Repositionable Lotus Valve System—Post-Market Evaluation of Real World
Clinical Outcomes [RESPOND]; NCT02031302) (J Am Coll Cardiol Intv 2019;12:38–49) © 2019 The Authors.
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LVOT = left ventricular
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Surgeons
TAVR = transcatheter aortic
replacement
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39T ranscatheter aortic valve replacement(TAVR) is a safe and effective treatment forpatients with symptomatic severe aortic ste-
nosis at intermediate or high surgical risk (1–5). With
the expansion of TAVR eligibility to include lower-
risk patients, management of procedure-related com-
plications is increasingly important, along with a
focus on longer-term outcomes.
Common complications of TAVR include vascular
complications, bleeding, valve malpositioning, resid-
ual paravalvular leak (PVL) between the native
annulus and prosthetic valve frame, and new-onset
conduction disturbances. The design of the Lotus
valve (Boston Scientiﬁc, Marlborough, Massachusetts)
helps to mediate a number of these complications.
Notably, Lotus uses controlled mechanical expansion
to permit optimal placement of the valve, making it
fully repositionable and retrievable, and has a unique
adaptive seal designed to minimize PVL (6,7). Recent
changes to the valve design include the addition of
Depth Guard technology, which limits the depth of the
valve frame during deployment, reducing the inter-
action of the valve with the left ventricular outﬂow
tract (LVOT) and conduction system.SEE PAGE 50The REPRISE (Repositionable Percutaneous
Replacement of Stenotic Aortic Valve Through Im-
plantation of Lotus Valve System) I and II studies
demonstrated the safety and efﬁcacy of TAVR with
the Lotus valve in patients at high risk for surgical
valve replacement (8,9). The recent REPRISE III
(Safety and Efﬁcacy Study of Lotus Valve for Trans-
catheter Aortic Valve Replacement) randomized
controlled trial demonstrated comparable safety and
efﬁcacy with the Lotus valve and a self-expanding
TAVR valve, with signiﬁcantly less paravalvular
regurgitation with the Lotus valve, albeit a greater
need for permanent pacemaker implantation (10).
The RESPOND (Repositionable Lotus Valve Sys-
tem—Post-Market Evaluation of Real World Clinical
Outcomes) post-market registry is unique in that itfees from Boston Scientiﬁc and Edwards Lifesciences. Dr. Hildick-Smith has
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Manuscript received July 30, 2018; revised manuscript received October 24,evaluated TAVR with the Lotus valve in a
large population representative of current
clinical practice. Patients in the RESPOND
study had excellent clinical outcomes at 30
days, with low rates of all-cause mortality
and major/disabling stroke (2.6% and 2.2%,
respectively), and negligible PVL (no patients
had severe PVL, and moderate PVL was pre-
sent in only 0.3% of patients at hospital
discharge) (11). Approximately one-third of
patients required a new pacemaker at 30
days.Here, we report 1-year outcomes from the
RESPOND study, the largest population to date
treated with the Lotus valve in clinical practice.
Additionally, we report 30-day outcomes from an
extension cohort of the RESPOND study treated with
the next-generation Lotus valve with Depth Guard.
METHODS
STUDY AND DEVICE DETAILS. The RESPOND study,
a prospective, open-label, post-market registry at 41
centers in Europe, New Zealand, and Latin America,
enrolled 1,014 patients with symptomatic aortic ste-
nosis at elevated risk of serious surgical morbidity or
mortality, per heart team consensus. Study eligibility,
enrollment, and data collection in the main patient
cohort have been previously described (11). Following
completion of enrollment in the main cohort, the
RESPOND study also enrolled an Extension cohort
(n ¼ 50), which allowed for short-term assessment of
a modiﬁed delivery system and center-driven im-
plantation technique, both intended to reduce pace-
maker implantation risk. Patients in the Extension
cohort were enrolled at 6 centers in the Netherlands,
United Kingdom, and Poland.
The protocol was approved by the locally appoin-
ted institutional review boards/ethics committees;
the study was conducted in accordance with the In-
ternational Conference on Harmonization Guidelines
for Good Clinical Practice and the ethical principles
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40outlined in the Declaration of Helsinki. The study was
sponsored by Boston Scientiﬁc Corporation and
registered with ClinicalTrials.gov (NCT02031302). The
data and study protocol for this clinical trial may be
made available to other researchers in accordance
with Boston Scientiﬁc’s Data Sharing Policy on the
Boston Scientiﬁc website. All patients gave written
informed consent.
The Lotus valve, a bioprosthetic aortic valve
comprising a braided nitinol wire frame with 3 bovine
pericardial leaﬂets, is pre-mounted on a pre-shaped
delivery catheter and deployed via controlled me-
chanical expansion. A detailed description of the
implantation procedure is provided elsewhere (6,7,9).
A polymer membrane surrounds the lower half of the
Lotus valve and reduces PVL by ﬁlling the space be-
tween the native annulus and the prosthetic valve
frame. To provide hemodynamic stability, the Lotus
valve functions early in the deployment process, and
rapid pacing is not required. Repositioning or
retrieval of the valve is possible at any point before
uncoupling and release. The RESPOND study evalu-
ated Lotus valve sizes of 23 mm, 25 mm, and 27 mm,
for implantation in native annulus sizes $20 mm
to #27 mm. The Extension cohort was treated with
the Lotus valve with Depth Guard. The Depth Guard
technology modiﬁes the way the valve is deployed by
ensuring early anchoring of the lowest edge of the
Lotus valve in the LVOT, and aims to reduce the
interaction of the valve with the LVOT and conduc-
tion system. In the RESPOND Extension cohort, only
the 23-mm and 25-mm valves were available.
OUTCOMES MEASURES. Endpoints were assessed
according to Valve Academic Research Consortium
(VARC)-2 metrics (12). The primary endpoint of the
RESPOND study was all-cause mortality in the intent-
to-treat (ITT) population at 30 days and 1-year post-
procedure; the primary endpoint for the Extension
cohort was all-cause mortality in implanted patients
at 30 days post-procedure. Secondary outcomes
measured included clinical efﬁcacy and valve safety,
and the degree of aortic valve regurgitation. An in-
dependent medical reviewer adjudicated all-cause
mortality and stroke events. An independent core
laboratory (Cardialysis Core Laboratory, Rotterdam,
the Netherlands) evaluated all available echocardi-
ography studies at baseline, discharge, and 1-year
follow-up for Lotus valve hemodynamic perfor-
mance and grade of aortic valve regurgitation ac-
cording to VARC-2 criteria.
STATISTICAL METHODS. The analysis population for
the primary endpoint is the ITT population (all
enrolled subjects where there was an attempt toimplant the Lotus valve, regardless of whether the
Lotus valve was successfully implanted). The analysis
population for secondary outcomes includes only
subjects who had a Lotus valve implanted (as-treated
population). Data from the Extension cohort were not
pooled with the main cohort for any data analyses.
Baseline and outcome variables were summarized
using descriptive statistics. All p values were 2-sided
and were derived from either a 1-sample exact bino-
minal test (for safety endpoints), a generalized
McNemar’s test (for improvement in New York Heart
Association [NYHA] functional classiﬁcation), or a
paired t-test analysis (for change in hemodynamic
parameters among patients with echocardiographic
data available at both speciﬁed time points). Echo-
cardiographic data collected for each subject during
the study was independently analyzed by the core
laboratory in order to control for interobserver vari-
ability and minimize bias and inconsistencies. No
imputation of missing data was performed.
Univariate and multivariate analyses were per-
formed to identify potential predictors for mortality
at 1 year. The signiﬁcance level thresholds for entry
and exit of independent variables into the multivar-
iate model were set at 0.1. Parameters with p < 0.05
were considered as potential predictors from the
multivariate stepwise regression model.RESULTS
RESPOND STUDY PARTICIPANTS AND BASELINE
CHARACTERISTICS. The RESPOND main cohort
enrolled 1,014 patients between May 2014 and
February 2016; the as-treated population included
996 patients who were treated with a Lotus valve. No
patient discontinued follow-up prematurely or with-
drew from the study. Baseline patient and echocar-
diographic characteristics for the main cohort were as
described in the 30-day outcomes paper (11), and are
presented in brief in Table 1.
CLINICAL OUTCOMES. The rates of all-cause mor-
tality in the ITT population (N ¼ 1,014) at 30 days and
1 year were 2.6% and 12.0%, respectively (primary
endpoint, calculated per protocol as binary rates; p <
0.001 vs. pre-speciﬁed performance goal at 30 days).
One-year follow-up data were collected from nearly
all patients with a Lotus valve implanted (995 of 996;
99.9%); the minimum follow-up time was 1 year for
all patients in this analysis (median [interquartile
range] follow-up was 389 [363 to 721] days)
(Figure 1A). The cumulative all-cause mortality rate at
1 year was 11.7% (Figure 2, Table 2). In a post hoc
subgroup analysis, patients with a higher left
TABLE 1 Baseline Clinical and Echocardiographic Characteristics
for the RESPOND As-Treated Population (N ¼ 996)
Age, yrs 80.8  6.5
Female 50.8
STS score* 6.0  6.9
Katz Index Activities of Daily Living Score 5.6  1.0
Diabetes mellitus, medically treated 22.4
COPD, moderate or severe 7.7
NYHA functional class III or IV 69.5
Atrial ﬁbrillation, history 33.9
Coronary artery disease, history 56.1
Prior PCI 29.8
Prior CABG 12.3
Cerebrovascular accident, history 9.5
Prior implanted pacemaker 13.3
Echocardiographic assessments—core lab
Aortic valve area (effective oriﬁce area), cm2 0.7  0.2
Mean aortic valve gradient, mm Hg 38.0  15.5
Peak aortic valve gradient, mm Hg 61.9  24.2
Left ventricular ejection fraction, % 49.8  10.5
Aortic regurgitation, moderate or severe† 11.7
Values are mean  SD or %. *Risk scores were not routinely collected/reported by
all study centers. †Severe in 14 patients (1.5%).
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary
disease; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary
intervention; RESPOND ¼ Repositionable Lotus Valve System—Post-Market Eval-
uation of Real World Clinical Outcomes trial; STS ¼ Society of Thoracic Surgeons.
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41ventricular ejection fraction (i.e., >40%) at baseline
had a lower likelihood of death at 1 year, whereas
history of chronic obstructive pulmonary disease,
dialysis-dependent renal failure, or atrial ﬁbrillation
were found to be signiﬁcantly associated with greater
mortality (Figure 3).
The rate of disabling stroke at 1 year was 4.1%; 17
patients (1.7%) had experienced a disabling stroke
after 30 days. At 1 year, 319 patients had a permanent
pacemaker implanted (32.3% among all patients;
37.2% among patients who did not have a pacemaker
at baseline); a total of 20 patients required a new
pacemaker after 30 days. Additional 1-year safety
outcomes for the as-treated population are shown in
Table 2.
ECHOCARDIOGRAPHIC OUTCOMES. Transthoracic echo-
cardiography assessment at 1 year was available
for core laboratory evaluation in 62.6% of
RESPOND patients (551 of 880 surviving patients) and
demonstrated that the improvement in valve hemo-
dynamics observed post-TAVR was sustained at 1 year
(Figure 4). Aortic valve area (effective oriﬁce area)
improved from 0.7  0.2 cm2 at baseline to 1.8  0.5
cm2 at discharge and 1.8  0.4 cm2 at 1 year (p < 0.001
vs. baseline). Mean aortic valve gradient declined
from 38.0  15.5 mm Hg at baseline to 10.8  4.6mm Hg at hospital discharge (p < 0.001 vs. baseline),
and remained 10.8  5.1 mm Hg at 1 year (p < 0.001 vs.
baseline; p ¼ 0.42 vs. discharge). PVL was absent or
trace in 94.5% of patients at 1 year (Figure 5A). There
were no patients with severe PVL; 0.4% of patients
exhibited moderate PVL, and 5.1% of patients had
mild PVL. Paired analysis of the change in PVL over
time was performed in patients with available trans-
thoracic echocardiography at discharge and 1 year
(n ¼ 531). Mild or less PVL was recorded at hospital
discharge in 528 of the patients in the analysis and
was maintained over the course of the year; only 1
patient (0.2%) was assessed as having moderate PVL
at 1 year. Conversely, of the 3 patients in the analysis
with moderate PVL at discharge, 2 (66.7%) exhibited
only mild PVL at 1 year.
NYHA FUNCTIONAL STATUS AND HEATH STATUS.
At baseline, 62.4% of patients were NYHA functional
class III; an additional 7.1% were class IV (Figure 6A).
The signiﬁcant improvement in NYHA functional
class at 30 days post-procedure was maintained at 1
year, with nearly 90% of surviving patients classiﬁed
as NYHA functional class I or II; 79% and 31% of pa-
tients had improved at least 1 or 2 classes, respec-
tively, relative to baseline (p < 0.001 for both).
Health-related quality of life, as measured by the self-
rated EuroQoL EQ-5D questionnaire, was signiﬁcantly
improved from baseline at 30 days post-procedure,
with improvements sustained through 1 year
(Table 3). The change in patients’ self-reported score
on the Visual Analog Scale was representative of a
clinically meaningful change in overall quality of
life (13).
RESPOND EXTENSION COHORT. The RESPOND
Extension cohort enrolled 50 patients between June
2016 and October 2016 (Figure 1B); baseline patient
and echocardiographic characteristics are shown in
Table 4. Patients enrolled in the Extension cohort
were generally similar to those in the main study
cohort, with the exception of having a slightly lower
baseline Society of Thoracic Surgeons (STS) score.
Successful vascular access, delivery, and deployment,
and successful retrieval of the delivery system were
achieved in 100% of patients. Valve repositioning was
attempted in 16 of 50 patients (32%), with 100%
success.
Thirty-day clinical follow-up was available for all
patients. There were no procedural deaths, and no
deaths at 30 days. The overall stroke rate was 6.0%;
2.0% of patients experienced a disabling stroke. The
permanent pacemaker implantation rate at 30 days
was 18.0% among all patients, and 20.0% among pa-
tients who did not have a pacemaker at baseline.
FIGURE 2 Cumulative Mortality Rate in RESPOND Main Cohort Through 1 Year
The rate of all-cause mortality through 1 year was similar in the intent-to-treat (gray dashed line) and as-treated (blue line) populations.
Chart shows cumulative event rates  1.96 SE. ITT ¼ intent-to-treat; RESPOND ¼ Repositionable Lotus Valve System—Post-Market Eval-
uation of Real World Clinical Outcomes trial.
FIGURE 1 Patient Disposition
(A) The RESPOND study enrolled 1,014 patients in the main cohort (intent-to-treat population), 996 of whom were implanted with a Lotus
valve (as-treated population). At 1 year, 995 patients had sufﬁcient follow-up or had a clinical event (116 patients had died). Echocardio-
graphic data at 1 year were available for core laboratory evaluation in 551 of the 880 surviving patients (62.6%). (B) The RESPOND Extension
cohort comprised 50 patients treated with the Lotus valve with Depth Guard, all of whom had 30-day clinical follow-up available (there were
no deaths at 30 days). Echocardiographic data at hospital discharge were available for 37 of the 50 Extension cohort patients (74.0%).
RESPOND ¼ Repositionable Lotus Valve System—Post-Market Evaluation of Real World Clinical Outcomes trial; TEE ¼ transesophageal
echocardiography; TTE ¼ transthoracic echocardiography.
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TABLE 2 Clinical Outcomes at 1 Year in the RESPOND
As-Treated Population (N ¼ 996)
All-cause mortality 116 (11.7)
Cardiovascular mortality 74 (7.6)
All stroke 48 (4.9)
Disabling stroke 40 (4.1)
Major vascular complications 34 (3.4)
Life-threatening or disabling bleeding 35 (3.6)
Acute kidney injury (stage 2 or 3) 17 (1.7)
Myocardial infarction 18 (1.9)
Repeat procedure for valve-related dysfunction 2 (0.2)
Hospitalization for valve-related symptoms or CHF 78 (8.3)
New onset atrial ﬁbrillation or atrial ﬂutter 33 (3.3)
Prosthetic valve thrombosis 8 (0.8)
Prosthetic valve endocarditis 13 (1.4)
Permanent pacemaker implantation
Among all patients 319 (32.3)
Among patients without pacemaker
at baseline (n ¼ 864)
319 (37.2)
Values are n (%) based on Kaplan-Meier rates.
CHF ¼ congestive heart failure; RESPOND ¼ Repositionable Lotus Valve
System—Post-Market Evaluation of Real World Clinical Outcomes trial.
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43Additional safety outcomes for the RESPOND Exten-
sion cohort are shown in Table 5.
Echocardiographic data at hospital discharge were
available for 37 of 50 patients (74%). Aortic valve area
(effective oriﬁce area) was 0.7  0.2 cm2 at baselineFIGURE 3 1-Year Mortality Across Patient Subgroups in the RESPON
An analysis was performed across different patient subgroups to identify
is from the Wald test. CABG ¼ coronary artery bypass graft; COPD ¼ chr
fraction; PCI ¼ percutaneous coronary intervention; RESPOND ¼ Reposi
Clinical Outcomes trial; STS ¼ Society of Thoracic Surgeons.and 1.7  0.3 cm2 at discharge (p < 0.001). Mean aortic
valve gradient declined from 39.8  13.7 mm Hg at
baseline, to 11.8  4.4 mm Hg at discharge (p < 0.001).
There were no patients in the Extension cohort with
moderate or severe PVL; 86.5% of patients exhibited
no or trace PVL, and 13.5% of patients had mild
PVL (Figure 5B). At baseline, 51.0% of patients were
NYHA functional class III, and 2.0% were class IV
(Figure 6B). At 30 days post-procedure, over 95% of
surviving patients were classiﬁed as NYHA functional
class I or II, with 72.3% and 27.7% of patients having
improved at least 1 or 2 classes, respectively
(p < 0.001 for both).DISCUSSION
One-year outcomes from the RESPOND study conﬁrm
the safety and efﬁcacy of the Lotus valve when used
in contemporary clinical practice (Figure 7). The
mortality rate in the implanted population was 11.7%,
and patients maintained excellent valve hemody-
namics with minimal paravalvular regurgitation. One-
year post-TAVR, 99.8% of patients who had been
assessed as having mild or less PVL at hospital
discharge maintained mild or less PVL over the course
of the year; no patients had severe PVL, and only
0.4% of patients exhibited moderate PVL.D Main Cohort
baseline variables potentially associated with death at 1 year; p value
onic obstructive pulmonary disease; LVEF ¼ left ventricular ejection
tionable Lotus Valve System—Post-Market Evaluation of Real World
FIGURE 5 Aortic Valve Regurgitation
Echocardiographic data were independently assessed by a core laboratory in the RESPOND main cohort (A) at baseline, hospital discharge, and
1 year post-procedure, and in the RESPOND Extension cohort (B) at baseline and hospital discharge. In both cohorts, the majority of patients
exhibited no/trace paravalvular leak (PVL) following Lotus valve implantation. RESPOND ¼ Repositionable Lotus Valve System—Post-Market
Evaluation of Real World Clinical Outcomes trial.
FIGURE 4 Valve Hemodynamics in the RESPOND Main Cohort
Improvements from baseline in mean aortic valve pressure gradient and mean aortic valve area were maintained at 1 year (p< 0.001 for both).
Echocardiographic data were independently assessed by a core laboratory. Data are mean  SD; p values are derived from a paired t-test
analysis among patients with data available at both baseline and 1 year. RESPOND ¼ Repositionable Lotus Valve System—Post-Market
Evaluation of Real World Clinical Outcomes trial.
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FIGURE 6 Change in NYHA Functional Status
(A) In the RESPOND main cohort, the improvement in NYHA functional class at 30 days post-procedure was maintained at 1 year. (B) The
majority of patients in the RESPOND Extension cohort also exhibited improved NYHA functional status at 30 days. NYHA status was not
recorded at all sites for all patients. Improvement from baseline to 30 days or 1 year was evaluated for patients with data available at both
time points; p value is from a generalized McNemar’s test. NYHA ¼ New York Heart Association; RESPOND ¼ Repositionable Lotus Valve
System—Post-Market Evaluation of Real World Clinical Outcomes trial.
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45The 1-year survival data from the RESPOND study
are comparable to 1-year clinical outcomes in other
large TAVR trials/registries of patients with similar
risk (mean baseline STS score in the RESPOND study
was 6.0%). In the PARTNER 2A (Placement of AoRTic
TraNscathetER Valves) intermediate-risk patient
cohort (N ¼ 1,011; mean STS: 5.8%) (4) mortality at 1
year was 12.3% in patients treated with the SAPIEN
XT valve (Edwards Lifesciences, Irvine, California),
and 3.4% of patients had moderate PVL. Patients
treated transfemorally with the SAPIEN 3 valve in the
SOURCE 3 (Observational Study to Evaluate Safety
and Performance of SAPIEN 3 THV System in Real Life
Practice) post-market registry (N ¼ 1,694; median lo-
gistic EuroSCORE 13.96) (14) had a 12.6% mortalityTABLE 3 Health Status in RESPOND Main Cohort as Evaluated by EQ-
Baseline 30 Days
EQ-5D Index values
(U.K.-based population algorithm)
0.64  0.24 (715) 0.71  0.26 (7
EQ Visual Analog Scale 57.2  18.0 (719) 66.7  19.0 (71
Values are mean  SD (n). p value is from a paired t-test for continuous variables.
EQ-5D ¼ EuroQol 5D; RESPOND ¼ Repositionable Lotus Valve System—Post-Market Erate at 1 year, and moderate PVL was observed in 2.7%
of patients (an increase from the 1.2% observed at
discharge). In a multivariate analysis of the SOURCE 3
data, the strongest baseline characteristics predictive
of 1-year mortality were log EuroSCORE, renal insuf-
ﬁciency, moderate to severe tricuspid regurgitation,
and atrial ﬁbrillation. Among patients treated with
the CoreValve System (Medtronic, Minneapolis,
Minnesota) in the ADVANCE registry (CoreValve
Advance International Post Market Study) (N ¼ 1,015;
median STS: 5.3%) (15), mortality was 17.9% at 1 year,
and 12% of patients had moderate or greater PVL. And
in the large, multivalve GARY registry (German Aortic
Valve Registry) (16), patients who underwent trans-
vascular TAVR (N ¼ 2,694; mean log EuroSCORE5D Quality of Life Questionnaire
1 Year
p Value
Baseline to 30 Days 30 Days to 1 Year Baseline to 1 Year
20) 0.71  0.26 (704) <0.001 0.946 <0.001
9) 68.0  18.2 (707) <0.001 0.172 <0.001
valuation of Real World Clinical Outcomes trial.
TABLE 5 Clinical Outcomes at 30 Days in the RESPOND
Extension Cohort (N ¼ 50)
All-cause mortality 0 (0)
Cardiovascular mortality 0 (0)
All stroke 3 (6)
Disabling stroke 10 (2)
Major vascular complications 1 (2)
Access site related 1 (2)
Life-threatening or disabling bleeding 0 (0)
Acute kidney injury (stage 2 or 3) 1 (2)
Myocardial infarction 0 (0)
Repeat procedure for valve-related dysfunction 0 (0)
Hospitalization for valve-related
symptoms or CHF
0 (0)
Prosthetic aortic valve malapposition* 0 (0)
Coronary obstruction (periprocedural) 0 (0)
Cardiac tamponade (periprocedural) 0 (0)
Prosthetic valve thrombosis 0 (0)
Prosthetic valve endocarditis 0 (0)
New onset atrial ﬁbrillation or atrial ﬂutter 2 (4)
Permanent pacemaker implantation
Among all patients (n ¼ 50) 9 (18)
Among patients without pacemaker
at baseline (n ¼ 45)
9 (20)
Values are n (%) and are binary rates among patients with sufﬁcient clinical
follow-up or death, or who had an adverse event. *Includes valve migration, valve
embolization, ectopic valve deployment, or transcatheter aortic valve (TAV)-in-
TAV deployment.
Abbreviations as in Table 2.
TABLE 4 Baseline Clinical and Echocardiographic Characteristics
for RESPOND Extension Cohort (N ¼ 50)
Patient characteristics
Age, yrs 80.9  8.2
Female 54
STS score* 4.4  3.1
Katz Index Activities of Daily Living Score 5.9  0.4
Diabetes mellitus, medically treated 30
COPD, moderate or severe 2
NYHA functional class III or IV 52
Atrial ﬁbrillation, history 34
Coronary artery disease, history 62
Prior PCI 28
Prior CABG 14
Cerebrovascular accident, history 12
Prior implanted pacemaker 10
Echocardiographic assessments, core lab
Aortic valve area (effective oriﬁce area), cm2 0.7  0.2
Mean aortic valve gradient, mm Hg 39.8  13.7
Peak aortic valve gradient, mm Hg 64.0  19.5
Left ventricular ejection fraction, % 50.2  9.3
Aortic regurgitation, moderate or severe† 17.8
Procedural characteristics
Valve system implanted
23 mm 17 (34)
25 mm 33 (66)
Vascular access
Transfemoral 48 (96)
Transaortic 2 (4)
Subclavian 0 (0)
Values are mean  SD, %, or n (%). *Risk scores were not routinely collected/
reported by all study centers. †Severe in 1 patient (2.2%).
Abbreviations as in Table 1.
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4625.9%) had a 1-year mortality rate of 20.7%. Although
this higher mortality rate reﬂects a somewhat earlier
TAVR experience (procedures were performed in
2011), data from the GARY registry do provide insight
into the inﬂuence of PVL on mortality: long-term
survival was worst in patients with severe PVL
(50.0%), and patients with mild PVL had greater
mortality (25.3%) compared with those with trace
(23.3%) or no (21.2%) PVL.
The outcomes in the RESPOND population are also
comparable to those recently observed with the Lotus
valve in the REPRISE III randomized controlled trial
(N ¼ 607; mean STS 6.7) (Figure 8) (10). In the
REPRISE III study, the cumulative 1-year mortality
rate in Lotus-treated patients was 11.4%, 4.0% of
patients had experienced a disabling stroke, and
moderate PVL was observed in 0.9% of patients. The
rates of major vascular complications or bleeding
were numerically lower in the RESPOND study
compared with REPRISE III, which may reﬂect agreater familiarity and experience with the Lotus
valve among operators in the RESPOND study
compared with the REPRISE III study. Because the
RESPOND study was a post-market registry, most
operators had experience implanting the Lotus valve
before enrolling patients. By contrast, most REPRISE
III sites did not have prior experience with the Lotus
valve before enrolling patients in the trial. Addition-
ally, patients in the REPRISE III study were slightly
older and had a slightly higher STS score at baseline
compared with patients in the RESPOND study. Such
differences in baseline risk may also have contributed
to the lower rates of vascular complications and
bleeding events in the RESPOND study. A higher
overall stroke rate was recorded in the REPRISE III
study compared with the RESPOND study, perhaps
due to differences in reporting requirements (the
REPRISE III protocol speciﬁed a neurological exam at
discharge and 1 year; the RESPOND protocol did not).
These differences aside, the similarity in the overall
performance of the Lotus valve in the highly selected
REPRISE III population versus the RESPOND registry,
which more closely approximates unrestricted
FIGURE 7 Key Findings From the RESPOND Study and RESPOND Extension Cohort
In the RESPOND post-market registry and RESPOND Extension cohort, patients with severe aortic stenosis underwent transcatheter aortic valve replacement with,
respectively, the Lotus valve (n ¼ 996) or the Lotus valve with Depth Guard (n ¼ 50). Clinical follow-up 30 days post-implantation was available for all patients in
both groups; 1-year follow-up was available for 99.9% of patients in the RESPOND main cohort (1-year follow-up was not required per protocol for the Extension
cohort). Patients in both study cohorts exhibited a low mortality rate and excellent valve hemodynamics with minimal paravalvular regurgitation, as assessed by an
independent core laboratory. The outcomes from the RESPOND study and RESPOND Extension conﬁrm the safety and efﬁcacy of the Lotus valve when used in
contemporary clinical practice. Additionally, the observed rate of permanent pacemaker implantation at 30 days was lower in the Extension cohort (18%) compared
with the main cohort (34.6%), suggesting that modiﬁcations to the valve design (i.e., Depth Guard technology) and to the implant technique may aid in lowering the
pacemaker rate. PVL ¼ paravalvular leak; RESPOND ¼ Repositionable Lotus Valve System—Post-Market Evaluation of Real World Clinical Outcomes trial; TEE ¼
transesophageal echocardiography; TTE ¼ transthoracic echocardiography.
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47clinical practice, underscores the suitability and
adaptability of Lotus across the TAVR population.
It should be noted that the proportion of RESPOND
patients who received a new permanent pacemaker
within 1 year, 37.2%, remains high compared with
other contemporary studies/registries (PARTNER 2A
9.9% [4]; SOURCE 3 13.2% [14]; ADVANCE 26.4% [15];
GARY 26.2% [16]). A recent post hoc analysis of the
RESPOND study demonstrated that pacemakerimplantation following TAVR with the Lotus valve
was highly correlated with valve implantation depth;
however, PVL was not (17). Thirty-day outcomes from
the RESPOND Extension cohort corroborate the
following ﬁndings: patients treated with the Lotus
valve with Depth Guard, which effectively limits
valve implantation depth, had excellent clinical out-
comes at 30 days (0% mortality, and only 1 incidence
of disabling stroke), and no moderate or severe PVL
FIGURE 8 Comparison of 1-Year Outcomes With the Lotus Valve in the RESPOND Main Cohort and REPRISE III
Mortality, cardiovascular mortality, and disabling stroke at 1 year were similar in RESPOND and REPRISE III patients (10), whereas bleeding and vascular complications
were relatively more common among REPRISE III patients. Data shown are KM rates. *Risk scores were not routinely collected/reported by all RESPOND study centers.
†Among patients without a pacemaker at baseline. AF ¼ atrial ﬁbrillation/ﬂutter; CV ¼ cardiovascular; REPRISE III ¼ Safety and Efﬁcacy Study of Lotus Valve for
Transcatheter Aortic Valve Replacement trial; KM ¼ Kaplan-Meier; other abbreviations as in Figure 3.
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48was observed. Although the Extension cohort repre-
sents a small sample of patients treated with the
Lotus valve with Depth Guard, the observed rate of
permanent pacemaker implantation at 30 days
(20.0%) was lower than that seen with the original
Lotus valve (34.6%), suggesting it is possible to
reduce the pacemaker rate using a combination of
modiﬁcations to implant technique and valve design.
STUDY LIMITATIONS. The RESPOND study is not a
randomized study, and thus lacks a direct compar-
ator. Additionally, echocardiographic follow-up at 1
year was available for only 62.6% of the as-treated
population (551 of 880 surviving patients). The rate
of echo follow-up in the RESPOND study is similar to
that seen in contemporary TAVR studies/registries at
1 year (PARTNER 2A 72.0% [4]; SOURCE 3 60.4% [14];
ADVANCE 60.0% [15]). The RESPOND protocol re-
ﬂected standard practice, and 1-year echocardio-
graphic follow-up is not the standard of practice at all
institutions; it is often difﬁcult to get patients to re-
turn to the study site, particularly when they are
participating in a post-market registry. Because
longer-term echocardiographic data would aid in
understanding the impact of PVL on clinical out-
comes, the RESPOND study will continue to collect
such data at those sites for which annual echocar-
diographic follow-up is the standard of care.CONCLUSIONS
The RESPOND post-market study is unique in that, to
our knowledge, it is the only prospective TAVR reg-
istry presenting data with independent clinical event
adjudication and echocardiographic core laboratory
assessment at 1 year. One-year outcomes from the
RESPOND study conﬁrm the sustained safety and ef-
ﬁcacy of TAVR with the Lotus valve in a large popu-
lation treated in routine clinical practice. Early
experience with Lotus with Depth Guard suggests
that adaptations to implantation technique, in
conjunction with modiﬁcations to the valve design,
may lower the pacemaker implantation rate.
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PERSPECTIVES
WHAT IS KNOWN? Although transcatheter aortic valve
replacement is a valid treatment strategy for patients with
symptomatic severe aortic stenosis, additional evidence is
warranted as treatment expands to younger patients and
those at lower risk.
WHAT IS NEW? This report from the RESPOND post-
market registry conﬁrms favorable clinical outcomes and
sustained valve performance with the Lotus valve out to
1 year. Patients treated with the Lotus valve exhibited
excellent valve hemodynamics with minimal paravalvular
regurgitation, albeit with a high rate of conduction disorders
requiring permanent pacemaker implantation.
WHAT IS NEXT? Data from the RESPOND Extension
cohort suggest that adaptations to implantation tech-
nique, in conjunction with modiﬁcations to the valve
design (i.e., Depth Guard technology), may lower the
pacemaker implantation rate. Further Lotus valve itera-
tions and procedure experience that may help reduce
conduction disorders warrant additional research.
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